ezetimibe has been researched along with Dyslipidemias in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 48 (21.62) | 29.6817 |
| 2010's | 120 (54.05) | 24.3611 |
| 2020's | 54 (24.32) | 2.80 |
| Authors | Studies |
|---|---|
| Broncel, M; Gorzelak-Pabiś, P; Niedzielski, M; Woźniak, E | 2 |
| Arca, M; Pérez de Isla, L; Schiele, F; Vlachopoulos, C | 1 |
| Nishikido, T; Ray, KK | 1 |
| Choi, HD; Shin, KH | 1 |
| Kerins, M; McCaughey, C; Murphy, G; Murphy, R; Ranganathan, D | 1 |
| Ah, YM; Choi, HD; Jeong, M | 1 |
| Choi, J; Chung, JW; Hong, JH; Jeon, U; Kim, HD; Kim, W; Park, SH; Seong, K; Shin, WY | 1 |
| Banach, M; Lewek, J | 1 |
| Annibali, G; Aranzulla, T; Bianchi, F; Blandino, A; Bongioanni, S; Borrione, M; Carceri, C; Casati, R; Cerutti, E; Civera, S; Colopi, M; De Rosa, C; Delnevo, F; Gandolfo, N; Gasco, A; Giglio, C; Grossi, S; Luceri, S; Mabritto, B; Meliga, E; Muccioli, S; Musumeci, G; Parrini, I; Pizzuti, A; Scrocca, I; Sibona Masi, A; Tomasello, A | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Chilbert, MR; Clark, CM; Ma, Q; Salah, S; VanDuyn, D | 1 |
| Abdul-Rahman, T; Ahmad, S; Awuah, WA; Bandyopadhyay, D; Bukhari, SMA; Capriles, CAA; Corriero, AC; de Andrade, H; Goel, A; Gupta, R; Hajra, A; Herrera, EC; Lawrence, J; Mares, AC; Patel, N; Shah, R; Shaikh, R; Ulusan, S | 1 |
| Chao, TH; Chen, CP; Chou, MT; Hsieh, CH; Huang, CY; Jong, GP; Lee, IT; Lu, CH; McGirr, A; Sheu, WH | 1 |
| Alam, S; Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Gao, Q; Kosiborod, M; Mues, KE; Rosenson, RS; Shaik, A | 1 |
| Dubot, P; Ferrières, D; Ferrières, J; Jamme, T; Levade, T; Sabourdy, F; Verdier, C | 1 |
| Nussbaumerová, B | 1 |
| Ahn, JC; Cha, DH; Cho, EJ; Cho, JM; Choi, CU; Choi, SY; Gwon, HC; Han, KH; Han, KR; Hong, SJ; Hong, YJ; Jeong, HS; Jeong, YH; Jo, SH; Kang, HJ; Kim, BK; Kim, SH; Kim, WS; Lee, SY; Park, TH; Woo, SI | 1 |
| Chang, Y; Eom, S; Kim, M; Song, TJ | 1 |
| Kladovikova, OV; Larin, VG; Larina, VN; Makhova, UV; Mironova, TN; Orlov, DA; Varlamova, YY | 1 |
| Campuzano Ruiz, R; Cosín-Sales, J; Díaz Díaz, JL; Escobar Cervantes, C; Fernández Olmo, MR; Gómez-Doblas, JJ; Mostaza, JM; Pedro-Botet, J; Plana Gil, N; Valdivielso, P | 1 |
| Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY | 1 |
| Bramlage, P; Brandts, J; Brix, JM; Danne, T; Heyer, CHJ; Holl, RW; Müller-Wieland, D; Tittel, SR; Zimny, S | 1 |
| Corsini, A; Ferri, N; Ruscica, M; Santos, RD | 1 |
| Lee, J; Lee, SH | 1 |
| Iihara, N; Nakatsuma, A; Sato, T; Senda, S; Tomida, J; Yoshida, T | 1 |
| Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T | 1 |
| Abe, S; Hashimoto, R; Hasumi, H; Hirose, S; Inoue, T; Masuyama, T; Numao, T; Sakuma, M; Toyoda, S; Waku, R; Yazawa, H | 1 |
| Bang, CN; Boman, K; Egstrup, K; Greve, AM; Kesäniemi, YA; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 2 |
| Ballantyne, CM; Bhatt, DL; Cannon, CP; de Lemos, JA; Elliott-Davey, M; Kosiborod, MN; Liu, Y; Mues, KE; Rosenson, RS; Yazdi, D | 1 |
| Kludtke, EL; Kopecky, SL; Oren, O | 1 |
| Sattar, N; Sillars, A | 1 |
| Noack, F; Noutsias, M; Rohe, K; Schlitt, A; Treede, H; Waßmuth, S | 1 |
| Kaszyńska, M; Żebrowski, P | 1 |
| Bilato, C; Coats, AJS; Drexel, H; Mollace, V; Perrone Filardi, P; Rosano, GMC; Spoletini, I | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, WD; Park, JY | 1 |
| Češka, R | 1 |
| Cicero, AFG; Fogacci, F; Strilchuk, L; Tocci, G | 1 |
| Allahyari, A; Hagström, E; Jernberg, T; Leosdottir, M; Lundman, P; Ueda, P | 1 |
| Christou, EA; Christou, GA; Christou, KA; Christou, MA; Kiortsis, DN; Mprikos, SG; Nikas, DN | 1 |
| Choksi, RR; Goldfaden, RF; Lewis, T; Niman, S; Rana, K; Reid, J; Sheikh-Ali, M | 1 |
| Daum, A; Gallego-Colon, E; Yosefy, C | 1 |
| Chen, YM; Chiang, WC; Chou, YH; Chu, TS; Lai, TS; Lin, SL; Lin, YC; Tu, YK; Wu, HY | 1 |
| Chatterjee, S; Chiu, SW; Feinn, R; Pratt, CM | 1 |
| Paquot, N; Wallemacq, C | 1 |
| Agrawal, H; Albert, MA; Auyoung, M; Choy, HK; Liu, J | 1 |
| Ideishi, A; Kumagai-Koyanagi, N; Kuwano, T; Miura, SI; Morita, H; Suematsu, Y; Tashiro, K | 1 |
| Kazimuddin, M; Mittal, S; Singh, A | 1 |
| Boccara, F; Rosenson, RS | 1 |
| Bobbert, T; Combes, G; Duparc, T; Genoux, A; Grenkowitz, T; Hollstein, T; Ingueneau, C; Kassner, U; Martinez, LO; Perret, B; Ruidavets, JB; Schumann, F; Steinhagen-Thiessen, E | 1 |
| Chang, D; Cheng, Y; Su, X | 1 |
| Bruckert, E; Desamericq, G; Gusto, G; Khachatryan, A; Ngo, P; Sorio-Vilela, F | 1 |
| Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M | 1 |
| Anderson, TJ; Barry, AR; Couture, P; Dayan, N; Francis, GA; Genest, J; Grégoire, J; Grover, SA; Gupta, M; Hegele, RA; Lau, D; Leiter, LA; Leung, AA; Lonn, E; Mancini, GBJ; Manjoo, P; McPherson, R; Ngui, D; Pearson, GJ; Piché, ME; Poirier, P; Sievenpiper, J; Stone, J; Thanassoulis, G; Ward, R; Wray, W | 1 |
| Arashi, H; Hagiwara, N; Ogawa, H; Ogiso, M; Otsuki, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Pottle, A; Quoraishi, SH; Reynolds, TM | 1 |
| Athyros, VG; Boutari, C; Karagiannis, A | 1 |
| Andretta, M; Avogaro, A; Degli Esposti, L; Fadini, GP; Morieri, ML; Perrone, V; Plebani, M; Veronesi, C; Vigili de Kreutzenberg, S | 1 |
| Fujisue, K; Tsujita, K | 1 |
| Ballantyne, CM; Beacham, LA; Miller, DL; Nicholls, SJ; Nissen, SE; Ray, KK; Riesmeyer, JS; Ruotolo, G | 1 |
| Arashi, H; Endoh, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Adhyaru, BB; Jacobson, TA | 1 |
| Kampangkaew, J; Nambi, V; Pickett, S | 1 |
| Humphries, KH; Mancini, GBJ | 1 |
| Choby, B | 1 |
| Chemburkar, A; Gogtay, J; Jadhav, UM; Lopez, M; Wander, GS | 1 |
| Bernik, MMS; Cerda, A; Dorea, EL; Fajardo, CM; Guimarães, ES; Gusukuma, MC; Hirata, MH; Hirata, RDC; Pinto, GA | 1 |
| Agrawal, S; Fornoni, A; Smoyer, WE; Zaritsky, JJ | 1 |
| Cervelli, N; Ferri, C; Tocci, G | 1 |
| Bujas-Bobanovic, M; Ginsberg, HN; Henry, RR; Letierce, A; Louie, MJ; Müller-Wieland, D; Taub, PR | 1 |
| Jacoby, D; Russell, C; Sheth, S | 1 |
| Ahmed, H; Bin Riaz, I; Kaluski, E; Khan, SU; Krasuski, R; Nasir, F; Rahman, H; Riaz, H; Sattur, S; Talluri, S | 1 |
| Akeroyd, JM; Ballantyne, CM; Bittner, VA; Kennedy, KF; Masoudi, FA; Morris, PB; Petersen, LA; Stone, NJ; Virani, SS | 1 |
| Arashi, H; Endo, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Sekiguchi, H; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Packard, CJ | 1 |
| Canullo, L; Casu, G; Cercone, S; Cuccia, C; De Ferrari, GM; Di Biase, M; Gitt, AK; Guasti, L; Horack, M; Lautsch, D; Nicosia, A; Perna, GP; Picco, F; Strazzella, C; Totaro, R | 1 |
| Katsimardos, A; Kiouri, E; Kotakos, C; Rallidis, LS | 1 |
| Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E | 1 |
| Laufs, U; Lütjohann, D; Schulze, PC; Weingärtner, O | 1 |
| Robinson, JG; Watson, KE | 1 |
| Rana, JS; Warraich, HJ | 1 |
| Cabrera Mateos, JL; García Díaz, E; Morera Porras, ÓM; Ramírez Medina, D | 1 |
| Athyros, V; Karagiannis, A; Katsiki, N; Reklou, A | 1 |
| Hegele, RA; Tsimikas, S | 1 |
| Costa, D; Napoli, C; Scognamiglio, M; Sorriento, A | 1 |
| Han, SN; Tao, HL; Yang, WH; Yin, JJ; Zhang, LR | 1 |
| Anagnostis, P; Georgiou, T; Goulis, DG; Lambrinoudaki, I; Paschou, SA; Vaitsi, K; Veneti, S | 1 |
| Simons, LA | 1 |
| Hattori, E; Hirao, K; Kasano, K; Matsumoto, S; Nakamura, S; Teng, Y; Tokunaga, T; Yamamoto, T; Yonetsu, T; Yoshiwara, H | 1 |
| Fichtenbaum, CJ; Gebhardt, A | 1 |
| Fujimoto, G; Hayashi, A; Matsui, N; Piao, Y; Tokita, S; Umeda, T | 1 |
| Araújo, F; Ferreira, J; Fontes-Carvalho, R; Gavina, C; Marques Silva, P; Morais, J; Rodrigues, E | 1 |
| Gupta, YK; Padhy, BM; Yadav, R | 1 |
| Ballantyne, CM; Catapano, AL; Norata, GD | 1 |
| Akinsanya, KO; Castro-Perez, J; Chen, Y; Daniels, E; Johns, DG; Previs, SF; Roddy, TP; Wang, SP; Zhou, H | 1 |
| Chia, SM; Davis, HR; Hentze, H; Jensen, KK; Johns, DG; Shaw, RJ; Shih, SJ; Wong, KK | 1 |
| Ban, MR; DeGorter, MK; Hegele, RA; Kim, RB; Schwarz, UI; Tirona, RG; Ziada, A | 1 |
| Abe, K; Taneyama, T; Teramoto, T | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Watson, K; Yoon, CH | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y | 1 |
| Goldberg, LR; Makkar, KM; Sanoski, CA; Spinler, SA | 1 |
| Bajnok, L | 1 |
| Hamai, J; Kamiko, K; Kawasaki, S; Kondo, Y; Nezu, U; Shigematsu, E; Takahashi, M; Takano, T; Terauchi, Y; Yamada, M; Yamakawa, T; Yamazaki, S; Yoshii, T | 1 |
| Arnaoutoglou, EM; Kouvelos, GN; Matsagkas, MI; Milionis, HJ; Papa, N; Raikou, VD | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 2 |
| Iwasaka, T; Jo, F; Kubo, R; Kusabe, M; Morimoto, S; Morita, T; Nakahigashi, M; Nakano, C; Okuno, Y; Seo, M; Shiojima, I; Someya, K; Takahashi, N; Toyoda, N; Ueda, H | 1 |
| Hirano, T; Kashiwabara, Y; Koba, S; Kobayashi, Y; Kohyama, N; Murayama, JI; Ohbayashi, M; Yamamoto, T | 1 |
| Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV | 1 |
| Annoni, F; Caputo, S; Cremona, AM; Grandi, AM; Grossi, P; Guasti, L; Marchesi, C; Maresca, AM; Nicolini, E; Rizzi, L | 1 |
| Cofán, M; Forga, MT; Larrousse, M; Leyes, P; Martínez, E; Pérez-Heras, AM; Ros, E; Trabal, J | 1 |
| AbuMweis, SS; Frohlich, J; Jones, PJ; Marinangeli, CP | 1 |
| Brudi, P; Catapano, AL; Farnier, M; Foody, JM; Tershakovec, AM; Tomassini, JE; Toth, PP | 1 |
| Barkas, F; Elisaf, M; Kostapanos, MS; Liberopoulos, E; Mikhailidis, DP; Milionis, H | 1 |
| Hegele, RA; McPherson, R | 1 |
| Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR | 1 |
| Catapano, AL | 1 |
| Moschetta, A | 1 |
| Federici, M | 1 |
| Sekhar, RV | 1 |
| Irie, Y; Kanamaru, Y; Kaneto, H; Katakami, N; Katsura, T; Kosugi, K; Kubo, F; Nakashoutani, I; Okusu, T; Sakamoto, K; Shimomura, I; Yamamoto, Y; Yoshiuchi, K | 1 |
| Ambegaonkar, B; Davies, G; Ejzykowicz, F; Hsu, TY; Laires, PA | 1 |
| Cífková, R; Krajčoviechová, A | 1 |
| Golledge, J; Guerrero-Romero, F; Sahebkar, A; Simental-Mendía, LE; Watts, GF | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Kramer, W | 1 |
| Knight, M; Sando, KR | 1 |
| Elkind, MS; Yaghi, S | 1 |
| Banach, M; Mikhailidis, DP; Serban, MC | 1 |
| Cacciotti, L; Campolongo, G; Gaudio, C; Marazzi, G; Pelliccia, F; Quattrino, S; Rosano, G; Volterrani, M | 1 |
| Kanno, K; Kishikawa, N; Mizooka, M; Sugiyama, A; Tazuma, S; Yokobayashi, K | 1 |
| Ako, J; Fujiyoshi, K; Hashikata, T; Hashimoto, T; Ishii, S; Kakizaki, R; Kameda, R; Kitasato, L; Namba, S; Nemoto, T; Shimohama, T; Tojo, T; Yamaoka-Tojo, M | 1 |
| Baila-Rueda, L; Cenarro, A; Civeira, F | 1 |
| Couture, P; Drouin-Chartier, JP; Lamarche, B; Lemelin, V; Lépine, MC; Tremblay, AJ | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Barrera-Durán, C; González-Ortiz, M; Hernández-Salazar, E; Martínez-Abundis, E | 1 |
| Ashraf, TB; Ballantyne, CM; Cressman, MD; Gill, GG; Hunter, JA; Johnson-Levonas, AO; Kher, U; Mitchel, YB; Shah, S | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH | 1 |
| Duarte, F; Ginsberg, HN; Khavandi, M; Reyes-Soffer, G | 1 |
| Chen, PY; Chien, KL; Choo, DW; Chou, CH; Ho, W; Lin Wu, FL; Lin, ZF; Wang, J; Wang, YW; Wu, YJ | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A | 1 |
| Miura, S; Saku, K | 1 |
| Mandell, BF | 1 |
| Díaz Gómez, JM | 1 |
| Burgos, D; Cabello, M; González Molina, M; Gutiérrez, C; Gutiérrez, E; López, V; Sola, E | 1 |
| Borrego Domínguez, JM; Guisado Rasco, A; Lage Gallé, E; Martínez Martínez, A; Mogollón Jiménez, MV; Sánchez Brotons, JA; Sobrino Márquez, JM | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Berneis, K; Rini, GB; Rizzo, M; Spinas, GA | 1 |
| Hughes, S | 1 |
| Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA | 1 |
| Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S | 1 |
| Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S | 1 |
| Jones, PH | 1 |
| Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Chen, RY; Goodman, SG; Jaffer, S; Langer, A; Leiter, LA; Mendelsohn, AA; Teoh, H; Theriault, L; Tjia, S | 1 |
| Aoyama, N; Hatakeyama, Y; Izumi, T; Kosugi, R; Machida, Y; Masuda, T; Tojo, T; Yamaoka-Tojo, M; Yoshida, Y | 1 |
| Costa, JA; González, C; Miralles, A; Pascual, JM; Pérez-Lahiguera, F; Rodilla, E | 1 |
| Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A | 1 |
| Charland, SL; Malone, DC | 1 |
| Day, A; Kumar, SS; LaHaye, SA; Lahey, KA | 1 |
| Michishita, I; Mizuguchi, I; Nozue, T | 1 |
| Hasegawa, K; Hiramitsu, S; Hishida, H; Ishiguro, Y; Kani, A; Kato, K; Matsubara, Y; Matsuyama, H; Noba, M; Ozaki, Y; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y | 1 |
| Dunn, FL | 1 |
| Briseño, GG; Mino-León, D | 1 |
| Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S | 1 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Polo Romero, FJ; Ramírez Relinque, L; Rodríguez Martín, B; Santisteban López, Y | 1 |
| Bianco, HT; Fonseca, FA; Fonseca, HA; Izar, MC | 1 |
| Alexanderson, E; Alexanderson, G; Calleja, R; García-Rojas, L; Jácome, R; Jiménez, M; Martínez, A; Meave, A; Ochoa, JM | 1 |
| Hattori, S; Hattori, Y | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Ahmed, MH; Khalil, AA | 1 |
| Jacobson, TA | 1 |
| Bays, HE; Gumbiner, B; Macdonell, G; Shah, A; Taggart, WV | 1 |
| Colquhoun, D; Hamilton-Craig, I; Kostner, K; Woodhouse, S | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Cardoso, SM; da Silva, PM | 1 |
| Sharma, M | 1 |
| Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Cordy, P; Garg, AX; Gomes, T; Hackam, DG; Juurlink, DN; Mamdani, M; Manno, M; Moist, L; Parikh, CR; Paterson, JM; Wald, R; Weir, MA; Yao, Z; Zhao, YY | 1 |
| Dayspring, TD; Phan, BA; Toth, PP | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 1 |
| Fukumoto, Y | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP; Theocharidou, E | 1 |
| Davidson, MH; Toth, PP | 1 |
| Mosca, L | 1 |
| Susekov, AV | 1 |
| Hegele, RA; Liu, DM; Miskie, BA; Tadiboyina, VT; Wang, J | 1 |
| Ballantyne, CM | 1 |
| Crawford, P; Saseen, J; Tweed, E | 1 |
| Cesena, FH; Luz, PL; Xavier, HT | 1 |
| Armani, A; Toth, PP | 1 |
| González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E; Ramos-Zavala, MG | 1 |
| Schulz, I | 1 |
| Ahmed, MH; Osman, MM; Saad, RA | 1 |
| Genest, J | 1 |
| Patel, J | 1 |
| Blanco, A; Bonjoch, A; Cinquegrana, D; Clotet, B; López-Blázquez, R; Moltó, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Rey-Joly, C | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Athyros, VG; Elisaf, M; Gazi, IF; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Maiques Galán, A | 1 |
| Backes, JM; Gibson, CA; Howard, PA | 1 |
| Carranza, J; Cervantes, JL; Fernández, P; González, CA; Leyva, JL; Morales, E; Pavía, A; Redding, FJ; Robles, FJ; Rodríguez, L; Rubio-Guerra, AF; Yza, R; Zacarías, JL | 1 |
| Ahmad, I; Hotiana, M; Hussain, M; Rahman, F; Ruby, E; Usman, H | 1 |
| Elisaf, M; Filippatos, T; Gazi, I; Kalogirou, M; Mikhailidis, DP; Saougos, V; Tselepis, AD; Tsimihodimos, V | 1 |
| Elisaf, M; Gazi, IF; Kalogirou, M; Kostapanos, M; Saougos, VG; Tambaki, AP; Tselepis, AD; Wolfert, RL | 1 |
| Agüero, J; Almenar, L; Izquierdo, M; Martínez-Dolz, L; Moro, J; Ortiz, V; Salvador, A; Sánchez-Lazaro, I | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
| Chrysohoou, C; Singh, S | 1 |
| Ballantyne, CM; Gimpelewicz, CR; Seper, C; Sirnes, PA; Stein, EA; Sussekov, A; Windler, E; Yigit, Z | 1 |
| Suckling, K | 1 |
| Branzi, A; Coccolo, F; Fallani, F; Grigioni, F; Magnani, G; Potena, L; Quarta, CC; Russo, A; Scalone, A | 1 |
86 review(s) available for ezetimibe and Dyslipidemias
| Article | Year |
|---|---|
Is it Time for Single-Pill Combinations in Dyslipidemia?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2022 |
The power of lipid registries for cardiovascular disease prevention.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Registries; Treatment Outcome | 2021 |
Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.
Topics: Anticholesteremic Agents; Atherosclerosis; C-Reactive Protein; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
Dyslipidemia Management in Pregnancy: Why Is It not Covered in the Guidelines?
Topics: Animals; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Proprotein Convertase 9 | 2022 |
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2022 |
Lipid Lowering Therapy: An Era Beyond Statins.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2022 |
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Secondary Prevention; Stroke | 2023 |
Fixed Combination for the Treatment of Dyslipidaemia.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2023 |
Management of Lipid Abnormalities in Patients with Diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2019 |
An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2020 |
An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Rosuvastatin Calcium; Treatment Outcome; Triglycerides | 2020 |
A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dicarboxylic Acids; Drug Combinations; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Receptors, LDL | 2020 |
Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; PCSK9 Inhibitors; Receptors, LDL; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2020 |
Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Drug Combinations; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipids; Male; Middle Aged; Patient Safety; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
Topics: Anticholesteremic Agents; Diabetes Mellitus; Double-Blind Method; Dyslipidemias; Ezetimibe; Humans; Incidence; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2020 |
[A decade of progress in the management of dyslipidemia].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2020 |
New possible pharmacological targets for statins and ezetimibe.
Topics: Animals; Atherosclerosis; Diabetic Angiopathies; Dyslipidemias; Endothelial Cells; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Signal Transduction | 2020 |
Coronary Artery Disease.
Topics: Animals; Anticholesteremic Agents; Autoimmunity; Biomarkers; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Periodicals as Topic; Phenotype; Risk Factors | 2020 |
Lipid-lowering therapy: Guidelines to precision medicine.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Precision Medicine; Proprotein Convertase 9 | 2021 |
Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
Topics: Benchmarking; Biomarkers; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention; Treatment Outcome; United Kingdom | 2021 |
Current status of lipid management in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; PCSK9 Inhibitors; Plaque, Atherosclerotic | 2017 |
Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Consensus; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Assessment | 2017 |
Advances in the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Proprotein Convertase 9; Risk Factors; Serine Endopeptidases; Triglycerides | 2017 |
Diabetes Update: Prevention and Management of Diabetes Complications.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cardiovascular Diseases; Depression; Diabetes Complications; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Dyslipidemias; Ezetimibe; Gastroparesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension | 2017 |
Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins; Nephrotic Syndrome; Niacin; Proprotein Convertase 9; Triglycerides | 2018 |
A Clinical Guide to Combination Lipid-Lowering Therapy.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors | 2018 |
A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Topics: Aged; Anticholesteremic Agents; Bayes Theorem; Biomarkers; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Risk Management; Triglycerides | 2018 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
Identifying Patients for Nonstatin Therapy.
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Decision-Making; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Risk Reduction Behavior; RNA, Small Interfering | 2018 |
Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dietary Supplements; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome; Vascular Stiffness | 2020 |
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors | 2019 |
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Topics: Asian People; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2019 |
Management of dyslipidaemias in the elderly population-A narrative review.
Topics: Aged; Cholesterol, LDL; Diet; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors | 2019 |
An updated review of lipid-modifying therapy.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Disease Management; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Proprotein Convertase 9; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Triglycerides | 2019 |
Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection.
Topics: Anti-Retroviral Agents; Drug Interactions; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Risk Assessment | 2019 |
Practical guide for the use of PCSK9 inhibitors in Portugal.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; PCSK9 Inhibitors; Portugal | 2019 |
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Topics: Azetidines; Benzimidazoles; Benzodiazepines; Carrier Proteins; Cholesterol, LDL; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Humans; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; Oxazolidinones; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2013 |
Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2014 |
[HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases | 2014 |
Implementing phytosterols into medical practice as a cholesterol-lowering strategy: overview of efficacy, effectiveness, and safety.
Topics: Anticholesteremic Agents; Azetidines; Dietary Supplements; Dyslipidemias; Ezetimibe; Humans; Phytosterols; Treatment Outcome | 2014 |
Combination therapy in dyslipidemia: where are we now?
Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Niacin; Patient Compliance; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome | 2014 |
Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Colesevelam Hydrochloride; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscular Diseases; Myalgia; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sex Factors; Vitamin D Deficiency | 2015 |
Nuclear receptors and cholesterol metabolism in the intestine.
Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol; Dyslipidemias; Ezetimibe; Fibroblast Growth Factors; Homeostasis; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Liver X Receptors; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear | 2015 |
Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lipoproteins; Liver; Metabolic Syndrome; Treatment Outcome | 2015 |
Treatment of dyslipidemia in HIV.
Topics: Anti-HIV Agents; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diet Therapy; Dyslipidemias; Exercise Therapy; Ezetimibe; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fibric Acids; Glutathione; Growth Hormone-Releasing Hormone; HIV Infections; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Niacin; Pyrazines; Thiazolidinediones; Triglycerides | 2015 |
Dyslipidemia and cardiovascular disease in women.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Contraindications; Dyslipidemias; Estrogen Replacement Therapy; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Menopause; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Simvastatin; Triglycerides; United States | 2015 |
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Regression Analysis; Serine Endopeptidases; Time Factors | 2015 |
Antilipidemic Drug Therapy Today and in the Future.
Topics: Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Triglycerides | 2016 |
Nonstatin therapies for management of dyslipidemia: a review.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clofibrate; Disease Management; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Proprotein Convertases; Risk Factors; Saccharomyces cerevisiae Proteins; Triglycerides; United States | 2015 |
Lipids and Cerebrovascular Disease: Research and Practice.
Topics: Brain Ischemia; Cerebral Hemorrhage; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Leukoencephalopathies; Lipoprotein(a); Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; Stroke; Triglycerides | 2015 |
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review.
Topics: Bile Acids and Salts; Cholesterol; Dyslipidemias; Ezetimibe; Humans; Membrane Proteins; Membrane Transport Proteins; Oxysterols; Phytosterols; Pravastatin; Sterols | 2016 |
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Life Style; Lipoproteins; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2017 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans | 2008 |
[Cardiovascular mortality in kidney transplatation].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Comorbidity; Coronary Angiography; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Humans; Kidney Diseases; Kidney Transplantation; Myocardial Ischemia; Obesity; Postoperative Complications; Preoperative Care; Prognosis; Risk Factors | 2008 |
The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?
Topics: Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Predictive Value of Tests; Reproducibility of Results; Treatment Outcome | 2009 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome | 2009 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels.
Topics: Animals; Anticholesteremic Agents; Arteries; Atherosclerosis; Azetidines; Biological Transport; Cholesterol; Chylomicrons; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Intestinal Absorption; Intestinal Mucosa; Intestines; Metabolic Syndrome; Rats | 2010 |
Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Treatment Outcome | 2010 |
'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Topics: Adult; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Practice Guidelines as Topic; Risk Factors; Young Adult | 2011 |
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Combination therapy for dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Niacin | 2011 |
Ezetimibe therapy: mechanism of action and clinical update.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Dyslipidemias; Ezetimibe; Humans; Intestinal Absorption; Jejunum; Lipids; Treatment Outcome | 2012 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
Ezetimibe therapy for dyslipidemia: an update.
Topics: Animals; Anticholesteremic Agents; Azetidines; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic | 2013 |
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
Topics: Azetidines; Cholesterol, HDL; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins, LDL; Simvastatin | 2005 |
Management of dyslipidemia in women in the post-hormone therapy era.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dietary Supplements; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin; Practice Guidelines as Topic; Triglycerides | 2005 |
[Ezetimib--inhibitor of cholesterol absorption: new perspectives in the treatment of dyslipidemia].
Topics: Anticholesteremic Agents; Azetidines; Dyslipidemias; Ezetimibe; Humans | 2005 |
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Risk Factors | 2005 |
Colesevelam hydrochloride in the management of dyslipidemia.
Topics: Allylamine; Anion Exchange Resins; Anticholesteremic Agents; Azetidines; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Patient Compliance | 2006 |
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Niacin | 2006 |
Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Treatment Outcome | 2006 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors | 2006 |
Statins and solid organ transplantation.
Topics: Adolescent; Adult; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Child; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Organ Transplantation; Risk Factors | 2006 |
Optimal lipid modification: the rationale for combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Research Design; Treatment Outcome | 2005 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2006 |
41 trial(s) available for ezetimibe and Dyslipidemias
| Article | Year |
|---|---|
Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study.
Topics: Aged; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hypercholesterolemia | 2022 |
A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hyp
Topics: Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Treatment Outcome | 2022 |
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Essential Hypertension; Ezetimibe; Humans; Hypertension; Losartan; Rosuvastatin Calcium; Treatment Outcome | 2023 |
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke | 2019 |
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Asymptomatic Diseases; Biomarkers; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; C-Reactive Protein; Dyslipidemias; Ezetimibe; Female; Humans; Male; Middle Aged; Quinolines; Single-Blind Method | 2020 |
Association between anemia and mortality in patients with acute coronary syndrome treated with percutaneous coronary intervention and contemporary lipid-lowering therapy.
Topics: Acute Coronary Syndrome; Anemia; Dyslipidemias; Ezetimibe; Female; Humans; Male; Percutaneous Coronary Intervention; Treatment Outcome | 2021 |
Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Biomarkers; Cholesterol Ester Transfer Proteins; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Time Factors; Treatment Outcome; United States | 2017 |
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Non-ST Elevated Myocardial Infarction; Prospective Studies; Quinolines; ST Elevation Myocardial Infarction; Treatment Outcome | 2017 |
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; India; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2013 |
The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Dyslipidemias; Elective Surgical Procedures; Ezetimibe; Female; Fluorobenzenes; Glomerular Filtration Rate; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vascular Surgical Procedures | 2015 |
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Azetidines; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Treatment Outcome; Young Adult | 2014 |
Renal and vascular protective effects of ezetimibe in chronic kidney disease.
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
Topics: Adult; Anticholesteremic Agents; Azetidines; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Ezetimibe; Female; Fenofibrate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2014 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.
Topics: Cholesterol; Coronary Artery Disease; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Single-Blind Method; Treatment Outcome | 2015 |
Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind Method; Duodenum; Dyslipidemias; Endoscopy, Digestive System; Ezetimibe; Gene Expression; Humans; Hydroxymethylglutaryl CoA Reductases; Insulin; Insulin Resistance; Male; Middle Aged; Proprotein Convertase 9; Real-Time Polymerase Chain Reaction; Receptors, LDL; RNA, Messenger; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2016 |
[Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Inulin; Male; Middle Aged; Simvastatin; Treatment Outcome | 2016 |
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Topics: Aged; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Niacin; Oxazolidinones; Treatment Outcome | 2017 |
Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Population Surveillance; Propensity Score; Survival Rate; Taiwan; Time Factors; Treatment Outcome | 2017 |
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pilot Projects; Pyrroles | 2008 |
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Deoxyguanosine; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acid-Binding Proteins; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Middle Aged; Proteinuria; Quinolines; Severity of Illness Index; Treatment Outcome; Triglycerides | 2010 |
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2010 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Lipoprotein(a); Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Triglycerides | 2010 |
The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Middle Aged; Obesity; Risk Factors; Triglycerides | 2010 |
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2010 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Triglycerides | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2011 |
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Azetidines; Blood Glucose; Blood Pressure Determination; Body Mass Index; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Ezetimibe; Female; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Obesity; Time Factors; Treatment Outcome | 2006 |
Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Treatment Outcome | 2007 |
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Dyslipidemias; Ezetimibe; Humans; Lipoproteins; Middle Aged; Osmolar Concentration; Particle Size | 2007 |
Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
Ezetimibe in heart transplantation: initial experience.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Heart Transplantation; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Time Factors | 2007 |
Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Male; Middle Aged; Muscular Diseases; Treatment Outcome; Triglycerides | 2008 |
Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2008 |
95 other study(ies) available for ezetimibe and Dyslipidemias
| Article | Year |
|---|---|
A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol.
Topics: Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Occludin; Risk Factors; Rosuvastatin Calcium; Zonula Occludens-1 Protein | 2021 |
Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.
Topics: Anticholesteremic Agents; Cardiac Rehabilitation; Cardiology; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2022 |
A Paradigm Shift in Dyslipidemia Management in Primary Care: A 12-Month Cohort Study.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Health Care; Rosuvastatin Calcium | 2022 |
[The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2022 |
Dyslipidemia: Are You Sure It Is Cholesterol?
Topics: Anticholesteremic Agents; Cholesterol; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans | 2021 |
Hypertension and dyslipidemia treament in stroke.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Brain Ischemia; Calcium Channel Blockers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indapamide; Stroke | 2022 |
[Current approaches to the treatment of patients with dyslipidemia in the real practice in the outpatient stage].
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Outpatients; Proprotein Convertase 9; Retrospective Studies | 2023 |
Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Perception; Proprotein Convertase 9; Spain; Treatment Outcome | 2023 |
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Austria; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fibric Acids; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Registries | 2023 |
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study.
Topics: Cardiovascular Diseases; Cohort Studies; Dyslipidemias; East Asian People; Ezetimibe; Female; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Secondary Prevention | 2023 |
Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Oxidative Stress | 2019 |
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Topics: Aged; Atherosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PCSK9 Inhibitors; Registries; Retrospective Studies; United States | 2020 |
Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Minnesota; PCSK9 Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Adherence To Lipid-Lowering Therapy In Patients With Coronary Heart Disease From The State Of Saxony-Anhalt, Germany.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; Coronary Disease; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipids; Male; Medication Adherence; Middle Aged; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
[Ezetimibe as a treatment for dyslipidaemia in CKD].
Topics: Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Insufficiency, Chronic | 2019 |
Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Humans; Male; Retrospective Studies; Rosuvastatin Calcium | 2020 |
Notes on the new “Recommendations for the treatment of dyslipidemia. Influencing of lipids to reduce cardiovascular risk”.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Proprotein Convertase 9; Risk Factors | 2020 |
Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Cardiology; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; PCSK9 Inhibitors; Percutaneous Coronary Intervention; Young Adult | 2020 |
High Tolerability of Pitavastatin Therapy: A Case Report of Comparison with other Statins.
Topics: Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Triglycerides | 2020 |
Changes in serum levels of angiopoietin-like protein-8 and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 after ezetimibe therapy in patients with dyslipidemia.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Anticholesteremic Agents; Azetidines; Carrier Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Peptide Hormones; Receptors, Lipoprotein | 2020 |
Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Dyslipidemias; Ezetimibe; HIV Infections; Humans | 2020 |
Reply: Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
Topics: Antibodies, Monoclonal, Humanized; Double-Blind Method; Dyslipidemias; Ezetimibe; HIV Infections; Humans | 2020 |
Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Biomarkers; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Spectroscopy; Male; Middle Aged; Particle Size; PCSK9 Inhibitors; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2020 |
Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Registries; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Registries; Rosuvastatin Calcium; Simvastatin | 2022 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Pregnancy; Pregnancy Complications; Primary Prevention; Risk Assessment; Secondary Prevention | 2021 |
Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Rosuvastatin Calcium; Treatment Outcome | 2021 |
Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Medication Adherence; Middle Aged; Primary Prevention; Retrospective Studies; Risk Assessment; Secondary Prevention; Time Factors; Treatment Outcome | 2021 |
Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Prospective Studies; Quinolines; Risk Factors | 2017 |
Lipid management in India: a nationwide, cross-sectional physician survey.
Topics: Cross-Sectional Studies; Dyslipidemias; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Risk Factors; Surveys and Questionnaires | 2017 |
Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Monocytes; RNA, Messenger; Simvastatin | 2017 |
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Proprotein Convertase 9; Risk Factors; Treatment Outcome | 2018 |
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Metabolic Syndrome; Middle Aged; PCSK9 Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Topics: Biomarkers; Cardiology; Cholesterol, LDL; Down-Regulation; Drug Prescriptions; Dyslipidemias; Ezetimibe; Guideline Adherence; Healthcare Disparities; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Professional Practice Gaps; Quality Indicators, Health Care; Registries; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; United States | 2018 |
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sitosterols; Time Factors; Treatment Outcome | 2018 |
Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Clinical Decision-Making; Coronary Disease; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Middle Aged; Patient Selection; PCSK9 Inhibitors; Registries; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Treatment Outcome | 2018 |
Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2018 |
Call for an ezetimibe effectiveness test.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
Reply to: "Call for an ezetimibe effectivess test".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Smoking; Young Adult | 2019 |
Lipid-Lowering Agents.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Benzimidazoles; Caproates; Cholesterol, HDL; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Dicarboxylic Acids; Dyslipidemias; Ezetimibe; Fatty Acids; Genetic Therapy; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoprotein(a); Oligonucleotides; RNA, Small Interfering | 2019 |
Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Time-to-Treatment; Treatment Outcome | 2020 |
Medication Adherence/Persistence and Demographics of Japanese Dyslipidemia Patients on Statin-Ezetimibe as a Separate Pill Combination Lipid-Lowering Therapy - An Observational Pharmacy Claims Database Study.
Topics: Administration, Oral; Administrative Claims, Healthcare; Adult; Age Factors; Aged; Anticholesteremic Agents; Comorbidity; Databases, Factual; Drug Combinations; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Pharmaceutical Services; Japan; Male; Medication Adherence; Middle Aged; Polypharmacy; Retrospective Studies; Risk Factors; Tablets; Time Factors; Treatment Outcome | 2019 |
In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.
Topics: Amides; Animals; Anticholesteremic Agents; Area Under Curve; Azetidines; Cholesterol; Cholesterol Ester Transfer Proteins; Cricetinae; Diet, High-Fat; Drug Evaluation, Preclinical; Dyslipidemias; Esters; Ezetimibe; High-Density Lipoproteins, Pre-beta; Humans; Intestinal Absorption; Male; Mesocricetus; Oxazolidinones; Sulfhydryl Compounds | 2013 |
Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins.
Topics: Animals; Azetidines; Cholesterol, Dietary; Cholesterol, LDL; Diet, High-Fat; Dyslipidemias; Ezetimibe; Macaca fascicularis; Proprotein Convertases; Serine Endopeptidases | 2013 |
Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy.
Topics: Aged; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Female; Glucuronides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies | 2013 |
Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study.
Topics: Aged; Azetidines; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Japan; Lipids; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Time Factors; Treatment Outcome; Triglycerides | 2013 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.
Topics: Adult; Aged; Allografts; Anticholesteremic Agents; Azetidines; Calcineurin Inhibitors; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Hospital Bed Capacity, 500 and over; Hospitals, Teaching; Humans; Immunosuppressive Agents; Male; Medical Records; Middle Aged; Retrospective Studies | 2013 |
Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Japan; Male; Middle Aged; Retrospective Studies; Risk Factors | 2014 |
Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; DNA Primers; Dyslipidemias; Ezetimibe; Female; Gene Frequency; Genotype; Humans; Japan; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Retrospective Studies; Triglycerides | 2014 |
Impact of drug policy on regional trends in ezetimibe use.
Topics: Anticholesteremic Agents; Azetidines; Canada; Drug Costs; Dyslipidemias; Ezetimibe; Follow-Up Studies; Health Policy; Humans; Prescription Drugs; Retrospective Studies | 2014 |
Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; HIV Infections; Humans; Lipid Metabolism; Male; Middle Aged; Phytosterols; Protease Inhibitors | 2014 |
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Therapy Management; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Risk Factors; Treatment Outcome; United States | 2015 |
Ezetimibe: rescued by randomization (clinical and mendelian).
Topics: Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Membrane Transport Proteins; Mutation; Phenotype; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2015 |
New insights on ezetimibe. Introduction.
Topics: Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Dyslipidemias; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lipids; Treatment Outcome | 2015 |
The usefulness of a cholesterol absorption inhibitor in Japanese type 2 diabetes patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Japan; Lipids; Male; Middle Aged | 2015 |
Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Portugal; Quality-Adjusted Life Years; Risk Factors; Rosuvastatin Calcium; Smoking | 2015 |
Long-term administration of a Niemann-Pick C1-like 1 inhibitor, ezetimibe, does not worsen bile lithogenicity in dyslipidemic patients with hepatobiliary diseases.
Topics: Anticholesteremic Agents; Bile; Cholesterol; Dyslipidemias; Ezetimibe; Fatty Liver; Female; Gallstones; Humans; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Phytosterols; Ursodeoxycholic Acid | 2016 |
Ezetimibe enhances and stabilizes anticoagulant effect of warfarin.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Blood Coagulation; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; International Normalized Ratio; Japan; Linear Models; Male; Middle Aged; Prothrombin Time; Retrospective Studies; Treatment Outcome; Warfarin | 2017 |
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic | 2017 |
A drug, a concept, and a clinical trial on trial.
Topics: Azetidines; Clinical Trials as Topic; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Humans; Research Design; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol; Creatine Kinase; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; L-Lactate Dehydrogenase; Lipids; Male; Middle Aged; Prospective Studies; Triglycerides | 2008 |
Safety and efficacy of ezetimibe in a sample of cardiac transplant patients.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Azetidines; Bilirubin; Cholesterol; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Heart Transplantation; Humans; Hypertension; Immunosuppressive Agents; Middle Aged; Retrospective Studies; Safety; Triglycerides | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Lipid Metabolism; Metabolic Syndrome; Niacin; Physical Examination; Risk Assessment; Risk Factors; Vitamin B Complex | 2009 |
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Topics: Adult; Arginine; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged | 2009 |
Achieving cholesterol goals. Current and future drug therapies.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin | 2003 |
The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.
Topics: Adult; Azetidines; C-Reactive Protein; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Simvastatin | 2009 |
Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Triglycerides | 2009 |
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies | 2009 |
[LDL-cholesterol goals and changes in C reactive protein in high coronary risk patients].
Topics: Aged; Azetidines; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Ezetimibe; Female; Humans; Longitudinal Studies; Male; Retrospective Studies; Risk Factors | 2009 |
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
Topics: Aged; Azetidines; Cost-Benefit Analysis; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mexico; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
[The best srategies to optimize lipid control: increasing statins dose or ezetimibe coadministration?].
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2010 |
Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia.
Topics: Anticholesteremic Agents; Azetidines; Dyslipidemias; Ezetimibe; Humans; Lipoproteins, LDL; Prognosis | 2010 |
Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: assessment by 13N-ammonia positron emission tomography.
Topics: Adenosine; Adolescent; Adult; Aged; Ammonia; Anticholesteremic Agents; Azetidines; Case-Control Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardium; Nitrogen Isotopes; Positron-Emission Tomography; Prospective Studies; Risk Factors; Simvastatin | 2010 |
Efficacy and safety of ezetimibe in patients undergoing hemodialysis.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Linear Models; Male; Middle Aged; Phytosterols; Renal Dialysis; Renal Insufficiency; Triglycerides | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Portugal; Simvastatin; Triglycerides | 2011 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
New fibrate use and acute renal outcomes in elderly adults: a population-based study.
Topics: Age Factors; Aged; Anticholesteremic Agents; Azetidines; Chronic Disease; Creatinine; Dyslipidemias; Ezetimibe; Female; Fibric Acids; Glomerular Filtration Rate; Hospitalization; Humans; Kidney Diseases; Male; Randomized Controlled Trials as Topic | 2012 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Nicotinic Acids; Probucol | 2012 |
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.
Topics: Adolescent; Amino Acid Sequence; Azetidines; Base Sequence; Child; Child, Preschool; Cholesterol Ester Storage Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins; Lovastatin; Male; Molecular Sequence Data; Sterol Esterase | 2005 |
Clinical inquiries. What are effective medication combinations for dyslipidemia?
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents | 2006 |
[Hypolipidemic therapy in special situations: hypothyroidism and liver disease].
Topics: Age Factors; Azetidines; Clofibrate; Drug Interactions; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Liver Diseases; Male; Sex Factors; Thyrotropin | 2005 |
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin | 2006 |
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Azetidines; Dyslipidemias; Ezetimibe; Female; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Prospective Studies; Treatment Outcome | 2006 |
[New indications and therapeutic objectives for dyslipidemia].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Dose-Response Relationship, Drug; Drug Design; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Research Design; Resins, Plant | 2006 |
Ezetimibe-induced acute pancreatitis.
Topics: Anticholesteremic Agents; Azetidines; Diagnosis, Differential; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lipase; Middle Aged; Pancreatitis, Acute Necrotizing | 2007 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |
The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Design; Dyslipidemias; Ezetimibe; Humans; Quinolines | 2008 |